Fail­ure in piv­otal PhI­II brain can­cer tri­al drags Is­rael's VBL Ther­a­peu­tics down

VBL Ther­a­peu­tics $VBLT is in cri­sis mode this morn­ing af­ter it an­nounced that its lead drug flunked a Phase III study in brain can­cer. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.